Economic Uncertainties Batter Trading in These 10 Firms

2. ImmunityBio Inc. (NASDAQ:IBRX)

ImmunityBio declined for a second consecutive day on Wednesday, shedding 10.79 percent to close at $2.48 apiece as investors sold off positions amid the broader market decline.

In recent news, IBRX announced that it has completed multiple submissions to the Food and Drug Administration, including a supplemental biologic license application for its novel immunotherapy Anktiva, which aims to treat unresponsive non-muscle invasive bladder cancer carcinoma in situ (CIS).

The company is also underway with the global expansion of Anktiva.

Just recently, it submitted a marketing authorization request to the European Medicines Agency for the review and assessment of the therapy. If approved by the EMA, IBRX would be able to sell ANKTIVA in 27 countries in Europe, including Norway, Iceland, and Liechtenstein.